Researchers built the first whole-organism, single-nucleus map of how rapamycin acts across every major tissue of the fruit fly, covering both sexes, four ages, and more than half a million cells. They found that rapamycin does not act evenly. It hits reproductive, digestive, and neuromuscular tissues hard while barely touching most neurons. Beneath this patchwork they uncovered a shared “Convergent Aging Trajectory” (CAT): aging cells from unrelated tissues drift toward one common metabolic state marked by mTORC1 activity and the rapamycin cofactor Fkbp12. Females accumulate more of these rapamycin-sensitive cells and clear more of them on the drug, which the authors argue explains why females live proportionally longer on rapamycin than males.
Rapamycin is the closest thing longevity science has to a proven pharmaceutical. It extends lifespan in yeast, worms, flies, mice and monkeys, and it does so by dialing down mTOR, the cell’s central nutrient-sensing switch. But a stubborn puzzle has followed the drug for years: its benefits are uneven. They shift with dose, timing, and, most conspicuously, sex. Nobody had a cell-by-cell picture of where in the body the drug actually does its work.
This study supplies that picture. Using single-nucleus RNA sequencing on more than 505,000 nuclei from male and female flies across the adult lifespan, the team constructed the Rapamycin Fly Cell Atlas, resolving 18 broad cell classes and 181 distinct cell types. When they asked which cells responded most strongly to rapamycin, the answer was not the brain. Reproductive tissues dominated, filling 7 of the top 15 most-affected cell types, alongside the fat body, gut, and muscle. Most neurons and glia barely flinched, likely because the large, greasy rapamycin molecule struggles to cross the blood-brain barrier.
The bigger idea emerged when the researchers compared aging cells across these different tissues. Aged nuclei from the female germline, the male accessory gland, and the nerve cord all converged on a strikingly similar transcriptional state: high glycolysis, high lipid synthesis, high mTORC1 signaling, and elevated Fkbp12, the protein rapamycin needs to bind before it can suppress mTOR. They named this shared endpoint the Convergent Aging Trajectory. It behaves like a common vulnerability. It builds up with age, and rapamycin preferentially strips it away.
Sex is where the story sharpens. Females accumulate more CAT-high cells across more tissues, and rapamycin clears them more thoroughly. That cellular difference tracks the organism-level result: females gained roughly 13 percent median lifespan on the drug versus roughly 7 percent in males. Rapamycin also preserved female fertility, muscle mass, neuromuscular junctions, and climbing ability into old age, while male benefits were smaller and appeared later in life.
The authors frame this as a shift in how we should evaluate longevity drugs: not only by the pathway they target, but by the specific aging cell states they erase. It is a resource and a hypothesis, generated in flies, and it now needs testing in mammals.
Actionable Insights
This is a fly mechanism paper, not a human trial, so take-home messages are directional rather than prescriptive.
Effect sizes, stated plainly. Rapamycin extended median lifespan by 8.8 days in females (68.9 to 77.7 days, a 12.8 percent gain) and 4.4 days in males (67.5 to 71.9 days, a 6.5 percent gain). The female advantage is roughly double the male advantage in relative terms. The drug also nearly doubled the sex gap in benefit despite identical dosing.
Dose matters and more is not better. The lower dose (20 micromolar) outperformed the ten-fold higher dose (200 micromolar) for lifespan in both sexes. This reinforces the human-relevant theme that intermittent or lower mTOR inhibition may beat aggressive suppression.
Sex likely modifies response. The data strongly suggest women and men may not benefit equally from mTOR inhibition, and the difference may be built into which aging cell states each sex accumulates. Anyone considering off-label rapamycin should treat sex as a real variable, not a footnote.
Functional payoffs, not just survival. In females, rapamycin preserved fertility (roughly 2-fold more offspring in aged females, p = 0.0019), maintained muscle mass, and improved climbing (a proxy for physical function). Healthspan, not only lifespan, moved.
None of this establishes a human dose, schedule, or safety profile. It is a reason to watch the sex-stratified human rapamycin trials closely.
Context and Source
- Open Access Paper: Rapamycin Mitigates a Sex-biased Convergent Aging Trajectory., July 3, 2026.
- Institutions: Baylor College of Medicine (Houston, USA); National Yang Ming Chiao Tung University and Academia Sinica (Taipei, Taiwan); Harvard Medical School and Howard Hughes Medical Institute (Boston, USA). Corresponding author: Hongjie Li, Baylor College of Medicine.
- Journal and Impact Evaluation: This is a preprint, not a peer-reviewed journal article. bioRxiv is a preprint server that does not perform peer review and does not carry a Journal Impact Factor or CiteScore.